{"id":"gcmaf-injections-100-ng","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL1944647","moleculeType":"Small molecule","molecularWeight":"5872.94"},"_fixedAt":"2026-03-30T17:05:05.463492","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GcMAF is a naturally occurring protein derivative that binds to macrophage receptors and stimulates their activation, enhancing phagocytosis and cytokine production. This mechanism is proposed to boost innate immunity against cancer cells and potentially viral infections. The protein is derived from vitamin D-binding protein (Gc-protein) and is thought to work by restoring immune function in patients with compromised macrophage activity.","oneSentence":"GcMAF (Gc-protein derived macrophage activating factor) activates macrophages to enhance immune surveillance and anti-tumor activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:45.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced cancer (various solid tumors and hematologic malignancies)"},{"name":"Chronic viral infections"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT06434077","phase":"PHASE3","title":"Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"S.LAB (SOLOWAYS)","startDate":"2025-08-20","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT02052492","phase":"PHASE1","title":"Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Efranat Ltd.","startDate":"2014-05","conditions":"Solid Tumors","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2022","pmid":"35217488","title":"Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto.","journal":"Cancer treatment and research communications"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GcMAF injections (100 ng)","genericName":"GcMAF injections (100 ng)","companyName":"S.LAB (SOLOWAYS)","companyId":"s-lab-soloways","modality":"Biologic","firstApprovalDate":"","aiSummary":"GcMAF (Gc-protein derived macrophage activating factor) activates macrophages to enhance immune surveillance and anti-tumor activity. Used for Advanced cancer (various solid tumors and hematologic malignancies), Chronic viral infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}